Hormonal contraceptives and venous thromboembolism: Are inflammatory bowel disease patients at increased risk? A retrospective study on a prospective database

Gianluca Pellino, Guido Sciudone, Francesca Caprio, Giuseppe Candilio, G. Serena De Fatico, Alfonso Reginelli, Silvestro Canonico, Francesco Selvaggi

Highlights

- Contraceptives do not increase the risk of VTE in IBD patients in remission.
- Irrespective of baseline disease, smoking is associated with VTE.
- IBD patients receiving contraceptives should be encouraged to quit smoking.

Abstract

Recent studies showed an increased risk of venous thromboembolism (VTE) in patients receiving oral hormonal contraceptives. Inflammatory bowel diseases (IBD) often affect young patients and represent a pro-coagulant condition. This could result from active inflammation, but a potential role for genetic and molecular factors has been suggested. Hormonal contraceptives have also been associated with increased risk of VTE and the risk may be greater in IBD patients that already are in a pro-coagulant status, but no definitive data are available in this population. The purpose of our study was to seek for differences of the risk of VTE in IBD patients receiving hormonal contraceptives compared with controls.

This is a retrospective study. We interrogated a prospectively maintained database of IBD patients observed at our outpatient clinic between 2000 and 2014. All female patients managed conservatively, with no active disease, who were taking oral hormone contraceptives in the study period, were included. Patients observed for other-than-IBD conditions at our Unit and at the Unit of Gynaecology and Obstetrics, receiving contraceptives, served as controls (ratio 1:2). Patients with cancer, those receiving hormonal therapy, and those with known genetic predisposition to VTE were excluded.

We included 146 six IBD patients and 290 controls. One patient in each group developed VTE. Overall, the incidence of VTE associated with oral contraceptives was 0.5%. IBD was associated with increased risk of VTE (OR 1.9, 95% CI 0.12–32.12, p > 0.99). Active smokers since 10 years (17.2%) had higher risks of VTE (OR 8.6, 95% CI 1.16–19.25, p = 0.03).

Our data show that patients with IBD in remission are not at higher risk of VTE due to oral oestrogen-containing contraceptives compared with non-IBD controls. Smokers are at increased risk, irrespective of the baseline disease.

© 2015 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Limited. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Inflammatory bowel diseases (IBD) are chronic inflammatory
conditions caused by complex etiopathogenetic mechanisms [1,2], which can affect patients at any age [3–8]. Crohn’s disease (CD) and ulcerative colitis (UC) are the most common IBD. Patients suffering from IBD are at increased risk of venous thromboembolism (VTE), i.e. deep vein thrombosis (DVT) and pulmonary embolism (PE) [9,10]. VTE can result from active inflammation, but it has also been suggested that more complex mechanisms may underlie the increased risk observed in IBD patients [9–11].

It has been reported that oral oestrogen-containing contraceptives are associated with increased risk of VTE, in so much that thrombotic events in contraception users younger than the age of 20 years account for 5–10% of total contraception-related VTE events in population-based studies [12].

It could be hypothesized that IBD and hormonal contraceptives play a synergistic role in increasing the risk of VTE, but no studies are available concerning this hypothesis, especially in patients without active inflammation.

Our aim was to seek for differences of the risk of VTE in female IBD patients receiving oestrogen-containing contraception compared with age-matched non-IBD controls.

2. Materials and methods

We retrospectively interrogated a prospectively maintained database of IBD patients observed at our Centre between January 2000 and June 2014. All female patients seen at our outpatient clinic who were not operated on and had no active disease were evaluated for inclusion. We included in our study all fertile, female IBD patients who were taking oral oestrogen-containing contraceptives in the study period.

A comparison group of controls was established with patients observed for other-than-IBD conditions at our Unit and at the Unit of Gynaecology and Obstetrics (ratio 1:2) [13–20]. Demographics and physical information of patients were collected from the clinical charts. Patients were phoned to collect additional information.

Exclusion criteria were as follows: 1) patients with cancer [21–24], 2) patients with active disease, 3) patients with known genetic predisposition to VTE, 4) patients who received surgery, and 5) ongoing hormonal therapy or treatment with immunodepressants (control group) in the study period. Control group patients who had conditions needing ambulatory or day surgery who were not operated on or accessed the Hospital for diagnostic purposes.

Life-style confounders for VTE were taken into account. As an example, smoking and being inactive increases the risk of VTE. Specifically, all patients were phoned or asked during follow-up visits to report on their occupation and level of physical activity, as well as smoking habit and duration. Patients were classified as A) “active”, if they had a physically demanding occupation, or if their leisure physical activities were equal or superior to 4/5 day per week., B) “moderately active”, if their leisure physical activities were between 2 and 4 per day per week, and C) “sedentary” if they had a sedentary occupation and physical activities were below 1 per day per week. This was made to disclose potential discrepancies between groups concerning factors that are associated with increased risk of VTE per se.

Outcome variable was the development of VTE while on oral hormonal contraceptive treatment. We sought for differences in the incidence of VTE in patients of both groups, and estimated the odds ratio (OR) associated with IBD in oral contraceptive receivers. A multivariate regression was run, in order to exclude potential confounders for VTE. OR is reported with 95% confidence intervals (95%). OR not including 1 and Fisher’s exact test results with p values < 0.05 were considered statistically significant.

3. Results

One-hundred forty-six IBD patients (49 CD, 97 UC), median age 27 (range 19–41) years fit in the criteria and were included. One CD developed DVT while receiving contraceptives. The control group included 290 patients. One patient developed DVT. No cases of PE were observed. Overall, the incidence of VTE associated with oral contraceptives was 0.5%. Median follow-up length was 7.3 (range 1–15) years in IBD and 6.9 (range 1–14) in controls (p = 0.81). Concerning baseline characteristics, the groups were similar (Table 1). Median age and median body mass index values were comparable. No differences were observed concerning patients classified as “active” (21 vs. 35), “moderately active” (46 vs. 82), and “sedentary” (79 vs 173, IBD vs controls, p = 0.09).

Baseline diseases of the control group were 1) benign coectaneous cysts (125), 2) groin or crural hernia (n = 68), and 3) minor vulvovaginal conditions (n = 97).

Patients with IBD were not at increased risk of VTE (OR 1.9, 95% CI 0.12–32.12, p > 0.99). Patients receiving immunosuppressant and biologic drugs showed a trend toward an increased risk of VTE (OR 5.6). This observation did not reach statistical significance (p = 0.3). When analysing patients who were active smokers since 10 years (17.2%), we found that this condition was significantly associated with an increased risk of VTE (OR 24.6, 95%CI 1.16–517.9, p = 0.03).

4. Discussion

In our study, we did not find an increased rate of VTE in female IBD patients in remission compared with non-IBD patients receiving oral hormonal contraceptives. Only two patients developed VTE overall, but prolonged exposure to tobacco smoking seemed to increase the odds of VTE, irrespective of the baseline disease.

CD and UC are the two principal IBD, which can affect people at any age and are characterised by a remitting-relapsing course [1–8,25–27], often requiring medical, surgical, or combined approaches [27–42]. Etiopathogenesis of IBD relies on complex interactions between autoimmune mechanisms and environmental factors, which have not been fully understood [1,25,26]. IBD patients are at increased risk of cancer [13,43–50], which is a risk factor for VTE, so we sought for malignancies and excluded such patients from the analysis.

In addition, IBD patients may suffer from extra-intestinal manifestations (EIMs), consisting of a plethora of accompanying symptoms and alterations occurring at organs not related to gastrointestinal tract. A pro-thrombotic status is observed in IBD patients, often accompanying active flares [9–11]. We hence removed from analysis patients with active IBD. The exact mechanism that leads to the increased risk of VTE in IBD patient is still to

| Table 1 Characteristics of patients and outcome. Data are n (%) or median (range). |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | IBD (n = 146)   | Controls (n = 290) | p                |
| Age, yr         | 26 (19–38)      | 27 (20–41)       | >0.09            |
| BMI kg/m²       | 22 (19–31)      | 22 (18–31)       | <0.09            |
| Occupation and lifestyle | 0.09 |
| - Active        | 21 (14.4)       | 35 (12)          |                  |
| - Moderately active | 46 (31.5)   | 82 (28.3)        |                  |
| - Sedentary     | 79 (54.1)       | 173 (59.7)       |                  |
| Venous thromboembolism | >0.99 |
| - DVT           | 1 (0.7)         | 1 (0.3)          |                  |
| - PE            | 0 (0)           | 0 (0)            |                  |

BMI: Body Mass Index; DVT: Deep Vein Thrombosis; PE: Pulmonary Embolism. IBD: Inflammatory Bowel Diseases.
be determined. These patients have been reported to have a protein genetic and bimolecular landscape that differs from that of general population in many aspects [1,2,5,6]. It is true that IBD patients often need surgery, and may have inflammation-driven systemic complications, but it also true that disease remission, either obtained with surgery or achieved with medications, is not able to control all of them [1,2,5–22]. Hence, compound pathways could produce this effect, not dissimilarly from those observed with EIMs.

Surgery is a relevant risk factor for VTE [11], so we also removed from the analysis patients who underwent any surgical procedure in the study period.

Studies have failed to identify a single cause of the increased risk of thrombosis in patients receiving oral hormonal contraceptives, but agreement exists concerning the higher rate of VTE observed in patients receiving such medications [12,51,52]. Although the efficacy of oral contraceptive in avoiding undesired pregnancies is high (99.7%), their use can increase the risk of VTE three to six times, and a relative risk as high as 0.7 and 1.6 of developing ovarian/endo-metrial and breast/cervical cancer, respectively [52]. Overall, the rate of VTE associated with oral contraceptive is very low in general population, not exceeding 0.06% [51,52]. We found a higher rate of VTE, and this could be justified by the fact that we enrolled subjects suffering from chronic diseases in outpatient settings rather than considering healthy population.

It has recently been reported that patients receiving such drugs have increased levels of free protein S and free tissue factor pathway inhibitor (TFPI), which are the two main determinants acquired resistance to activated protein C (APC), suggesting that VTE can be caused via this pathway [53].

Smoking increases the risk of VTE. In our series, a prolonged exposure to tobacco smoking significantly predicted a higher risk of subsequent VTE in patients receiving oral contraceptives, irrespective of their diagnosis. In our series, prolonged smoking predicted development of VTE, but it should be noted that the events only occurred in two patients overall. Even if our observations are limited by the small number of events, it may suggest clinical implications in IBD patients without active disease.

As IBD often require treatment with immunodepressant drugs and with biologics, which may increase the risk of VTE, we sought for a potential increased risk in such subgroup, but we failed to find any significant increased odds.

Our data must be read with caution. A significant limitation of our study is the small sample size, and the retrospective fashion. However, we used a prospective database and excluded patients operated on and those with active disease (confounders for VTE [54]), significantly reducing the number of patients suitable for inclusion observed at an ambulatory of Colorectal Surgery. Surgery plays a relevant role in IBD patients, and complex or repeated procedures can be needed [30–43,55–62]. This could have weakened the results, but at the same time is offering a snapshot on outpatient IBD subjects, and is providing IBD physicians with a practical, clinical insight on how to manage IBD patients willing to use oral contraceptives. Furthermore, no strong evidences are available concerning the risk of VTE associated with hormonal contraceptives in IBD patients [63]. The very recent Consensus Guidelines of the European Crohn’s and Colitis Organisation (ECCO) on reproduction and pregnancy concluded that hormonal contraceptives should be administered on an individual basis, taking into account other risk factors for VTE (e.g. smoking, previous surgery, disease activity, EIM) [64]. Moreover, extending the time frame for inclusion would have increased the risk of biases from changed medical management of patients as well as from hormonal contraceptive use [58–62].

Another limitation of our study could be not having performed routine ultrasound assessment of leg circulatory system seeking for asymptomatic DVT. However, it has been reported that such approach offers no advantages and is not cost effective in IBD patients in remission [65].

The length of follow-up was comparable among groups. It could be hypothesized that longer follow-ups could have increased the number of VTE episodes, however this should be considered under the light of actual exposure to hormonal contraceptives, and potential additional VTE could have been due to longstanding disease rather than contraceptives themselves.

In conclusion, IBD patients in remission do not seem to be at increased risk of developing VTE due to oral hormonal contraceptive use when compared with non-IBD patients. However, smoking and prolonged use of such medications should be discouraged due to the intrinsic risks of VTE. Administration of anticoagulants may be considered case-by-case in IBD patients taking oral contraceptives.

Ethical approval

The IRB of the Second University of Naples gave consent to conduct the study (observational study).

Source of funding

None declared.

Authors information

GP: Senior Resident in General Surgery Training Programme at Second Univ. of Naples.
GS: Associate Professor of Surgery at Second Univ. of Naples.
FC: Researcher in Gynaecology & Obstetrics at Second Univ. of Naples.
GC: Resident in General Surgery Training Programme at Second Univ. of Naples.
GSDF: Resident in General Surgery Training Programme at Second Univ. of Naples.
AR: Researcher in Radiology at Second University of Naples, Italy.
SC: Full Professor of Surgery at Second University of Naples, Italy.
FS: Associate Professor of Surgery at Second University of Naples, Italy.

Conflicts of interest

The authors declare that they have no conflict of interest to disclose.

Guarantor

Francesco Selvaggi, MD, EBSQ Colo.

Unit of General Surgery, Second University of Naples
Piazza Miraglia, 2 – 80138 Naples, Italy
Tel/fax: +39 818902291
Email: f.selvaggi@hotmail.com

References

[1] G. Latella, G. Rogler, G. Bamias, et al., Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD, J. Crohns Colitis 8 (2014) 1147–1165, http://dx.doi.org/10.1016/j.crohns.2014.03.008.
[2] L.C. Lawrence, G. Rogler, G. Bamias, et al., Cellular and molecular mediators of intestinal fibrosis, J. Crohns Colitis (2015 Nov 2) pii: j.crohns.2014.09.008. doi:
[54] H.H. Erem, R.P. Kiran, F.H. Remzi, J.D. Vogel, Venous thromboembolism in colorectal surgery: skip SCIP or comply? Tech. Coloproctol. 18 (2014) 719–724.

[55] G. Pellino, F. Selvaggi, Outcomes of salvage surgery for ileal pouch complications and dysfunctions, the experience of a referral centre and review of literature, J. Crohns Colitis 9 (2015) 548–557.

[56] G. Pellino, F. Selvaggi, G. Ghezzi, D. Corona, G. Riegler, G.G. Delaini, A think tank of the Italian society of colorectal surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: Crohn’s disease, Tech. Coloproctol 19 (2015) 639–651.

[57] F. Selvaggi, G. Pellino, Pouch-related fistula and intraoperative tricks to prevent it, Tech. Coloproctol. 19 (2015) 63–67.

[58] O.A. Catalano, M.S. Gee, E. Nicolai, et al., Evaluation of quantitative PET/MR enterography biomarkers for discrimination of inflammatory strictures from fibrotic strictures in Crohn disease, Radiology (2015 Oct 5) 150566 [Epub ahead of print], http://dx.doi.org/10.1148/radiol.2015150566.

[59] F. Selvaggi, G. Pellino, S. Canonico, G. Sciudone, Effect of preoperative biologic drugs on complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis, Inflamm. Bowel Dis. 21 (2015) 99–92.

[60] G. Pellino, F. Selvaggi, Surgical treatment of perianal fistulizing Crohn’s disease: from lay-open to cell-based therapy — an overview, Sci. World J. 2014 (2014) 146281, http://dx.doi.org/10.1155/2014/146281.

[61] G. Pellino, F. Selvaggi, From colon-sparing techniques to pelvic ileal pouch: history and evolution of surgery for ulcerative colitis, Eur. Surg. 47 (2015) 81–90.

[62] I. Wallstabe, N. Teich, Successful endoscopic incision of pouch-anal stricture in a patient with ulcerative colitis, Tech. Coloproctol. (2015 May 15), http://dx.doi.org/10.1007/s10151-015-1315-4 [Epub ahead of print].

[63] L.B. Zapata, M.E. Paulen, C. Canzano, et al., Contraceptive use among women with inflammatory bowel disease: a systematic review, Contraception 82 (2010) 72–85.

[64] C.J. van der Woude, S. Ardizzone, M.B. Bengtson, et al., The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease, J. Crohns Colitis 9 (2015) 107–124.

[65] G. Pellino, A. Reginelli, S. Canonico, F. Selvaggi, Prevalence of asymptomatic deep vein thrombosis in patients with inflammatory bowel diseases in the ambulatory surgery setting, Ambul. Surg. 21 (2015) 19–20.